XS-03 + bevacizumab + FOLFOX

XS-03 + bevacizumab + FOLFOX is a combination regimen under clinical investigation for treating **RAS-mutated metastatic colorectal cancer**. XS-03 is a small molecule **PLK1 modulator** developed by NovaOnco JS Therapeutics Co., Ltd. FOLFOX is a chemotherapy protocol composed of **folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin**, each with cytotoxic actions against rapidly dividing cells[2][4][5][6][8][10]. Bevacizumab is a **monoclonal antibody** targeting **VEGF-A**, inhibiting angiogenesis. The regimen aims to target multiple pathophysiological processes: cell cycle dysregulation (PLK1), DNA synthesis/disruption (FOLFOX), and tumor vascularization (bevacizumab)[1][5]. The primary indication is **metastatic colorectal cancer** with RAS mutation[1][5][7].

Other names

XS-03XS03XS 03bevacizumabFOLFOX